COVID-19 vaccine boosters not only protect against SARS-CoV-2 – the virus behind the most recent pandemic – but may also help protect against some future coronaviruses that risk spreading from animals to humans, Cambridge researchers have shown.
A drug commonly used to treat epilepsy could be repurposed to significantly boost the response to vaccines in humans, helping protect those for whom the vaccine is less effective, such as the elderly or immunocompromised.
Eight scientists from the fields of biomedical and health research at the University of Cambridge have been elected as Fellows of the Academy of Medical Sciences.
The mpox virus appears to be circulating silently in parts of Nigeria, in many cases without the symptoms typically associated with the disease, according to new research led by scientists from the University of Cambridge and partners in Nigeria. The findings may have implications for controlling the spread of the disease.
Bird flu viruses are a particular threat to humans because they can replicate at temperatures higher than a typical fever, one of the body’s ways of stopping viruses in their tracks, according to new research led by the universities of Cambridge and Glasgow.
Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the production of antibodies, new research from the University of Cambridge has shown.
Monoclonal antibodies – treatments developed by cloning a cell that makes an antibody – could help provide an answer to the growing problem of antimicrobial resistance, say scientists.
Nine Cambridge researchers are among the latest recipients of highly competitive and prestigious European Research Council (ERC) Starting Grants.
Problems with iron levels in the blood and the body’s ability to regulate this important nutrient as a result of SARS-CoV-2 infection could be a key trigger for long COVID, new research has discovered.
SARS-CoV-2 triggers the production of the antiviral protein IFN-γ, which is associated with fatigue, muscle ache and depression. New research shows that in Long COVID patients, IFN-y production persists until symptoms improve, highlighting a potential biomarker and a target for therapies.
© 2026 University of Cambridge